Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNA, U2 small nuclear 4, pseudogene (RNU2-4P) is annotated as a *pseudogene* of the U2 small nuclear RNA class. U2 small nuclear RNAs are major components of the spliceosome, responsible for pre-mRNA splicing, but pseudogene copies like RNU2-4P are generally considered nonfunctional and usually do not produce functional transcripts or proteins[1][5][6]. Functional U2 snRNAs (e.g., RNU2-1, RNU2-2) have established roles in mRNA maturation and have been investigated for disease associations and as potential biomarkers[2][3], but pseudogene variants such as RNU2-4P are not considered therapeutic targets, do not participate in canonical biological functions, and are not associated with drug interactions.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, U2 small nuclear 4, pseudogene (RNU2-4P).